Search

Your search keyword '"Verri, E."' showing total 231 results
Start Over Author "Verri, E."
231 results on '"Verri, E."'

4. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

Author

Iacovelli, R., primary, Ciccarese, C., additional, Brunelli, M., additional, Battelli, N., additional, Buttigliero, C., additional, Caserta, C., additional, Buti, S., additional, Santini, D., additional, Carella, C., additional, Galli, L., additional, Verri, E., additional, Ermacora, P., additional, Merler, S., additional, Masini, C., additional, De Vivo, R., additional, Milesi, L., additional, Spina, F., additional, Rizzo, M., additional, Sperduti, I., additional, Fornarini, G., additional, and Tortora, G., additional

Published
2022
Full Text
View/download PDF

5. Erratum: ☆Corrigendum to “Recommendations for surveillance and follow-up of men with testicular germ cell tumors: A multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica” (Critical Reviews in Oncology / Hematology (2019) 137 (154–164), (S1040842819300587), (10.1016/j.critrevonc.2019.03.006))

Author

Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, Da Pozzo, L, Di Nardo, D, Fornarini, G, Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., Da Pozzo L., Di Nardo D., Fornarini G., Galetti T. P., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., De Giorgi U., Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, Da Pozzo, L, Di Nardo, D, Fornarini, G, Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., Da Pozzo L., Di Nardo D., Fornarini G., Galetti T. P., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., and De Giorgi U.

Abstract

The authors regret that the affiliation of Drs. Barone and De. Giorgi in the Acknowledgements section is incorrect and should be as follows: Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy for Dr. Barone and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy for Dr. De Giorgi and The authors would like to apologise for any inconvenience caused.

Published
2020

6. Erratum: ☆Corrigendum to “Recommendations for surveillance and follow-up of men with testicular germ cell tumors: A multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica” (Critical Reviews in Oncology / Hematology (2019) 137 (154–164), (S1040842819300587), (10.1016/j.critrevonc.2019.03.006))

Author

Banna G. L., Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, Da Pozzo, L, Di Nardo, D, Fornarini, G, Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., Da Pozzo L., Di Nardo D., Fornarini G., Galetti T. P., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., De Giorgi U., Banna G. L., Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, Da Pozzo, L, Di Nardo, D, Fornarini, G, Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., Da Pozzo L., Di Nardo D., Fornarini G., Galetti T. P., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., and De Giorgi U.

Abstract

The authors regret that the affiliation of Drs. Barone and De. Giorgi in the Acknowledgements section is incorrect and should be as follows: Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy for Dr. Barone and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy for Dr. De Giorgi and The authors would like to apologise for any inconvenience caused.

Published
2020

7. Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center

Author

Aurilio, G, Verri, E, Frassoni, S, Bagnardi, V, Cossu Rocca, M, Cullura, D, Milani, M, Mascia, R, Curigliano, G, Orsi, F, Jereczek-Fossa, B, Musi, G, Omodeo Sale, E, De Cobelli, O, Nole, F, Aurilio G., Verri E., Frassoni S., Bagnardi V., Cossu Rocca M., Cullura D., Milani M., Mascia R., Curigliano G., Orsi F., Jereczek-Fossa B. A., Musi G., Omodeo Sale E., De Cobelli O., Nole F., Aurilio, G, Verri, E, Frassoni, S, Bagnardi, V, Cossu Rocca, M, Cullura, D, Milani, M, Mascia, R, Curigliano, G, Orsi, F, Jereczek-Fossa, B, Musi, G, Omodeo Sale, E, De Cobelli, O, Nole, F, Aurilio G., Verri E., Frassoni S., Bagnardi V., Cossu Rocca M., Cullura D., Milani M., Mascia R., Curigliano G., Orsi F., Jereczek-Fossa B. A., Musi G., Omodeo Sale E., De Cobelli O., and Nole F.

Abstract

OBJECTIVES: Bleomycin, etoposide, and cisplatin (BEP) is the most common and successful chemotherapy regimen for germ-cell tumor (GCT) patients, accompanied by a bleomycin-induced dose-dependent lung toxicity in certain patients. In an attempt to reduce bleomycin-toxicity, we developed a modified-BEP (mBEP) regimen. MATERIALS AND METHODS: Between August 2008 and February 2018, 182 unselected mainly testicular GCT patients (39 with adjuvant purpose and 143 with curative purpose) received a tri-weekly 5-day hospitalization schedule with bleomycin 15 U intravenous (IV) push on day 1 and 10 U IV continuous infusion over 12 hours on days 1 to 3, cisplatin 20 mg/m IV, and etoposide 100 mg/m IV on days 1 to 5. Pulmonary toxicity was assessed through chest computed tomography scan and clinical monitoring. RESULTS: Median number of mBEP cycles was 3 (range: 1 to 4). In the curative setting, according to the International Germ Cell Cancer Collaborative Group (IGCCCG) prognostic system, 112, 21, and 9 patients had good-risk, intermediate-risk, and poor-risk class, respectively; 66 (46%) patients had complete response (CR), 67 (47%) had partial response (52 of whom became CR afterwards), 6 (4%) had stable disease (that in 3 became CR afterwards), 3 (2%) progressed, and 1 (1%) died of brain stroke. At a median follow-up of 2.67 years (interquartile range: 1.23-5.00 y), 1 and 5-year overall survival and progression-free survival were 99% and 95%, and 90% and 88%, respectively. In the entire patient population, there was grade 3/4 neutropenia in 92 patients (51%), febrile neutropenia in 11 patients (6%), grade 1/2 nausea in 74 patients (41%), and no death due to pulmonary toxicity. CONCLUSION: In GCT patients, our mBEP-schedule would suggest an effective treatment modality without suffering meaningful pulmonary toxicity.

Published
2020

9. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial

Author

Ghi, M. G., Paccagnella, A., Ferrari, D., Foa, P., Alterio, D., Codecà, C., Nolè, F., Verri, E., Orecchia, R., Morelli, F., Parisi, S., Mastromauro, C., Mione, C. A., Rossetto, C., Polsinelli, M., Koussis, H., Loreggian, L., Bonetti, A., Campostrini, F., Azzarello, G., D’Ambrosio, C., Bertoni, F., Casanova, C., Emiliani, E., Guaraldi, M., Bunkheila, F., Bidoli, P., Niespolo, R. M., Gava, A., Massa, E., Frattegiani, A., Valduga, F., Pieri, G., Cipani, T., Da Corte, D., Chiappa, F., and Rulli, E.

Published
2017
Full Text
View/download PDF

10. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

Author

Iacovelli, Roberto R, Ciccarese, C, Brunelli, M, Battelli, N, Buttigliero, C, Caserta, C, Buti, S, Santini, D, Carella, C, Galli, L, Verri, E, Ermacora, P, Merler, S, Masini, C, De Vivo, R, Milesi, L, Spina, F, Rizzo, M, Sperduti, I, Fornarini, G, and Tortora, G

Subjects
PD-L1, Carcinoma, Transitional Cell, biomarkers, Hematology, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, cisplatin ineligible, Urinary Bladder Neoplasms, Oncology, Humans, bladder cancer, avelumab, immunotherapy, Cisplatin, Aged
Abstract

Cisplatin-based chemotherapy is the most recommended treatment for metastatic urothelial cancer (mUC). However, about 50% of patients are considered to be cisplatin ineligible. Anti-programmed cell death protein 1/programmed death-ligand 1 (PD-L1) therapies have, nevertheless, increased the options available to clinicians and are especially valuable for treating these patients. This study therefore tested the activity and safety of avelumab as first-line therapy for mUC.Patients with mUC who were ineligible for cisplatin-based chemotherapy were screened centrally for PD-L1 expression and only those with a tumour proportion score ≥ 5% were enrolled in the trial. The primary endpoint was 1-year overall survival (OS), and the secondary endpoints were median OS, median progression-free survival, overall response rate, duration of the response, safety and tolerability. All the survival rates were estimated with the Kaplan-Meier product-limit methodology and compared across groups using the log-rank test.A total of 198 patients were screened, with 71 (35.9%) whose PD-L1 expression was ≥5% enrolled in the study. The median age was 75 years, bladder cancer was the primary tumour in 73.2% of cases and 25.3% had liver metastases. The main reasons for the cisplatin ineligibility were a low rate of creatinine clearance (60 ml/min), present in 70.4% of patients, and an Eastern Cooperative Oncology Group performance status of 2, which affected 31%. The median OS was 10.0 months (95% confidence interval 5.5-14.5 months) and 43% of patients were alive at 1 year. A complete response was achieved in 8.5% of cases, and 15.5% had a partial response. Adverse any-grade and high-grade events occurred in 49.3% and 8.5% of patients, respectively. A grade 3 infusion reaction was the only high-grade treatment-related adverse event. No treatment-related deaths were reported.This ARIES trial confirmed the activity and safety of avelumab for treating mUC, adding a new therapy option to the armamentarium of checkpoint inhibitors already approved for platinum-ineligible, locally advanced/mUC.

Published
2022

11. First line avelumab in PD-L1+ve metastatic or locally advanced Urothelial Cancer (aUC) patients unfit for cisplatin: The ARIES trial

Author

Iacovelli, R., primary, Ciccarese, C., additional, Brunelli, M., additional, Battelli, N., additional, Buttigliero, C., additional, Caserta, C., additional, Buti, S., additional, Santini, D., additional, Naglieri, E., additional, Galli, L., additional, Verri, E., additional, Ermacora, P., additional, Milella, M., additional, Masini, C., additional, Aprile, G., additional, Milesi, L., additional, Spina, F., additional, Rizzo, M., additional, Sperduti, I., additional, Fornarini, G., additional, and Tortora, G., additional

Published
2022
Full Text
View/download PDF

13. Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica

Author

Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, DA POZZO, L, Di Nardo, D, Fornarini, G, Prayer Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., DA POZZO, LUIGI FILIPPO, Di Nardo D., Fornarini G., Prayer Galetti T., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., De Giorgi U., Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, DA POZZO, L, Di Nardo, D, Fornarini, G, Prayer Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., DA POZZO, LUIGI FILIPPO, Di Nardo D., Fornarini G., Prayer Galetti T., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., and De Giorgi U.

Abstract

Background: No compelling evidence is available about surveillance and follow-up of patients with testicular germ cell tumour (TGCT). Methods: In the light of the best clinical evidence, the Italian Germ cell cancer Group (IGG) and the Associazione Italiana di Oncologia Medica (AIOM) set up a multidisciplinary national consensus conference, involving 42 leading experts and 3 TGCT survivors. A minimum of 50% of votes was required in order to achieve a consensus recommendation on 29 questions. Results: Recommendations have been summarized in three tables, divided by stage I seminoma, stage I nonseminoma and the advanced disease, which may be useful for clinicians to appropriately choose the clinical investigation and its timing during the surveillance and follow-up of TGCT patients based on an accurate estimation of their risk of disease relapse. Conclusions: The IGG-AIOM consensus recommendations may help clinicians to choose appropriate clinical investigations for the surveillance and follow-up of TGCT patients.

Published
2019

16. PO-0995 Locally advanced nasopharyngeal carcinoma treated with a mixed beam (photons-protons) radiotherapy.

Author

Turturici, I., primary, Marvaso, G., additional, Alterio, D., additional, D’Ippolito, E., additional, Vischioni, B., additional, Ronchi, S., additional, Bonora, M., additional, Vitolo, V., additional, Mastella, E., additional, Magro, G., additional, Franco, P., additional, Krengli, M., additional, Fossati, P., additional, Ricotti, R., additional, Gandini, S., additional, Comi, S., additional, Camarda, A.M., additional, La Rocca, E., additional, Volpe, S., additional, Tagliabue, M., additional, Verri, E., additional, Orlandi, E., additional, Jereczek-Fossa, B.A., additional, and Orecchia, R., additional

Published
2021
Full Text
View/download PDF

19. Mixed-beam approach in locally advanced nasopharyngeal carcinoma: IMRT followed by proton therapy boost versus IMRT-only. Evaluation of toxicity and efficacy

Author

Alterio, (Alterio, D, 1 ), Daniela), D'Ippolito, (D'Ippolito, E, 2 ), Emma), Vischioni, (Vischioni, B, 2 ), Barbara), Fossati, (Fossati, P, Piero)(, 1, Gandini, 2, (Gandini, S, 3 ), Sara), Bonora, (Bonora, M, 2 ), Maria), Ronchi, (Ronchi, S, 2 ), Sara), Vitolo, (Vitolo, V, 2 ), Viviana), Mastella, (Mastella, E, 2 ), Edoardo), Magro, (Magro, G, 2 ), Giuseppe), Franco, (Franco, P, 4 ), Pierfrancesco), Ricardi, (Ricardi, U, 4 ), Umberto), Krengli, Marco, (Krengli, M, 5 ), Marco), Ivaldi, (Ivaldi, G, 6 ), Giovanni), Ferrari, (Ferrari, A, 1 ), Annamaria), Fanetti, (Fanetti, G, Giuseppi)(, 1, Comi, 7, (Comi, S, 8 ), Stefania), Tagliabue, (Tagliabue, M, 9 ), Marta), Verri, (Verri, E, Elena)( 10, ), Ricotti, (Ricotti, R, 2 ), Rosalinda), Ciardo, (Ciardo, D, 1 ), Delia), Jereczek-Fossa, (Jereczek-Fossa, Ba, Barbara Alicja)(, 1, Valvo, 7, (Valvo, F, 2 ), Francesca), Orecchia, (Orecchia, R, Roberto)(, 11, and Less, 12

Subjects
Male, medicine.medical_treatment, Severity of Illness Index, 030218 nuclear medicine & medical imaging, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Proton Therapy, Neoadjuvant therapy, Nasopharyngeal Carcinoma, Radiotherapy Dosage, Chemoradiotherapy, Hematology, General Medicine, Middle Aged, CHEMOTHERAPY, CANCER, Neoadjuvant Therapy, Progression-Free Survival, Oncology, 030220 oncology & carcinogenesis, Disease Progression, SURVIVAL, Female, Radiology, Adult, Mucositis, medicine.medical_specialty, Adolescent, Nasopharyngeal neoplasm, Xerostomia, Young Adult, 03 medical and health sciences, INTENSITY-MODULATED RADIOTHERAPY, 2-DIMENSIONAL RADIOTHERAPY, RADIATION, HEAD, ONCOLOGY, medicine, Humans, Dosimetry, Radiology, Nuclear Medicine and imaging, Radiation Injuries, Proton therapy, Aged, Neoplasm Staging, Retrospective Studies, Cancer staging, business.industry, Dose-Response Relationship, Radiation, Nasopharyngeal Neoplasms, medicine.disease, Radiation therapy, Nasopharyngeal carcinoma, Radiotherapy, Intensity-Modulated, business, Follow-Up Studies
Abstract

Objective: To compare radiation-induced toxicity and dosimetry parameters in patients with locally advanced nasopharyngeal cancer (LANPC) treated with a mixed-beam (MB) approach (IMRT followed by proton therapy boost) with an historic cohort of patients treated with a full course of IMRT-only. Material and methods: Twenty-seven patients with LANPC treated with the MB approach were compared to a similar cohort of 17 patients treated with IMRT-only. The MB approach consisted in a first phase of IMRT up to 54–60 Gy followed by a second phase delivered with a proton therapy boost up to 70–74 Gy (RBE). The total dose for patients treated with IMRT-only was 69.96 Gy. Induction chemotherapy was administrated to 59 and 88% and concurrent chemoradiotherapy to 88 and 100% of the MB and IMRT-only patients, respectively. The worst toxicity occurring during the entire course of treatment (acute toxicity) and early-late toxicity were registered according to the Common Terminology Criteria Adverse Events V4.03. Results: The two cohorts were comparable. Patients treated with MB received a significantly higher median total dose to target volumes (p = .02). Acute grade 3 mucositis was found in 11 and 76% (p = .0002) of patients treated with MB and IMRT-only approach, respectively, while grade 2 xerostomia was found in 7 and 35% (p = .02) of patients treated with MB and IMRT-only, respectively. There was no statistical difference in late toxicity. Local progression-free survival (PFS) and progression-free survival curves were similar between the two cohorts of patients (p = .17 and p = .40, respectively). Local control rate was 96% and 81% for patients treated with MB approach and IMRT-only, respectively. Conclusions: Sequential MB approach for LANPC patients provides a significantly lower acute toxicity profile compared to full course of IMRT. There were no differences in early-late morbidities and disease-related outcomes (censored at two-years) but a longer follow-up is required to achieve conclusive results.

Published
2020
Full Text
View/download PDF

22. PO-1218: Oligo Metastatic renal cell carcinoma: SBRT, if, when and how?

Author

Marvaso, G., primary, Corrao, G., additional, Oneta, O., additional, Gugliandolo, S.G., additional, Pepa, M., additional, Cecconi, A., additional, Gandini, S., additional, Piperno, G., additional, Cossu Rocca, M., additional, Verri, E., additional, Aurilio, G., additional, Corso, F., additional, Cullurà, D., additional, Rondi, E., additional, Vigorito, S., additional, Nolè, F., additional, Orecchia, R., additional, and Jereczek-Fossa, B.A., additional

Published
2020
Full Text
View/download PDF

23. On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2

Author

Caffo, O., primary, Zagonel, V., additional, Baldessari, C., additional, Berruti, A., additional, Bortolus, R., additional, Buti, S., additional, Ceresoli, G.L., additional, Donini, M., additional, Ermacora, P., additional, Fornarini, G., additional, Fratino, L., additional, Masini, C., additional, Massari, F., additional, Mosca, A., additional, Mucciarini, C., additional, Procopio, G., additional, Tucci, M., additional, Verri, E., additional, Zucali, P., additional, and Buttigliero, C., additional

Published
2020
Full Text
View/download PDF

24. Oligometastatic prostate cancer: Multidisciplinary treatment vs. standard of care

Author

Mistretta, F.A., primary, Collà Ruvolo, C., additional, Conti, A., additional, Verri, E., additional, Marvaso, G., additional, Luzzago, S., additional, Vizziello, D., additional, Sabatini, I., additional, Bilato, M., additional, Zagami, P., additional, Catellani, M., additional, Di Trapani, E., additional, Cozzi, G., additional, Bianchi, R., additional, Ferro, M., additional, Cordima, G., additional, Brescia, A., additional, Musi, G., additional, Jereczek-Fossa, B.A., additional, Nolè, F., additional, and De Cobelli, O., additional

Published
2020
Full Text
View/download PDF

29. Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

Author

Caffo, O., primary, Palesandro, E., additional, Nole, F., additional, Gasparro, D., additional, Mucciarini, C., additional, Aieta, M., additional, Zagonel, V., additional, Iacovelli, R., additional, De Giorgi, U.F.F., additional, Rossetti, S., additional, Fratino, L., additional, Ermacora, P., additional, Nicodemo, M., additional, Giordano, M., additional, Sartori, D., additional, Scapoli, D., additional, Verri, E., additional, Maines, F., additional, Pappagallo, G., additional, and Aglietta, M., additional

Published
2019
Full Text
View/download PDF

30. EP-1194 Acute toxicity in nasopharyngeal cancer patients treated with IMRT followed by proton therapy boost

Author

Alterio, D., primary, D’Ippolito, E., additional, Vischioni, B., additional, Ricotti, R., additional, Gandini, S., additional, Bonora, M., additional, Vitolo, V., additional, Mastella, E., additional, Magro, G., additional, Ronchi, S., additional, Franco, P.F., additional, Ricardi, U., additional, Krengli, M., additional, Comi, S., additional, Verri, E., additional, Ivaldi, G., additional, Jereczek-Fossa, B.A., additional, Valvo, F., additional, and Orecchia, R., additional

Published
2019
Full Text
View/download PDF

34. IMPACTO DA ARTRITE REUMATOIDE NA EFICIÊNCIA MASTIGATÓRIA

Author

Palinkas, M., primary, SIÉSSERE, S., additional, DE LUCA CANTO, G., additional, M. C. Rodrigues, L., additional, L. S. TAUBE, O., additional, D. VERRI, E., additional, B. DE VASCONCELOS, P., additional, G. DE SOUSA, L., additional, RIGHETTI, M.A., additional, G. PALINKAS, L., additional, H. REGALO, I., additional, and REGALO, S.C.H., additional

Published
2018
Full Text
View/download PDF

36. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial

Author

Ghi, M, Paccagnella, A, Ferrari, D, Foa, P, Alterio, D, Codecà, C, Nolè, F, Verri, E, Orecchia, R, Morelli, F, Parisi, S, Mastromauro, C, Mione, C, Rossetto, C, Polsinelli, M, Koussis, H, Loreggian, L, Bonetti, A, Campostrini, F, Azzarello, G, D'Ambrosio, C, Bertoni, F, Casanova, C, Emiliani, E, Guaraldi, M, Bunkheila, F, Bidoli, P, Niespolo, R, Gava, A, Massa, E, Frattegiani, A, Valduga, F, Pieri, G, Cipani, T, Da Corte, D, Chiappa, F, Rulli, E, Mione, CA, Niespolo, RM, Ghi, M, Paccagnella, A, Ferrari, D, Foa, P, Alterio, D, Codecà, C, Nolè, F, Verri, E, Orecchia, R, Morelli, F, Parisi, S, Mastromauro, C, Mione, C, Rossetto, C, Polsinelli, M, Koussis, H, Loreggian, L, Bonetti, A, Campostrini, F, Azzarello, G, D'Ambrosio, C, Bertoni, F, Casanova, C, Emiliani, E, Guaraldi, M, Bunkheila, F, Bidoli, P, Niespolo, R, Gava, A, Massa, E, Frattegiani, A, Valduga, F, Pieri, G, Cipani, T, Da Corte, D, Chiappa, F, Rulli, E, Mione, CA, and Niespolo, RM

Abstract

Background: Platinum-based chemoradiation (CCRT) is the standard treatment for Locally Advanced Head and Neck Squamous-Cell Carcinoma (LAHNSCC). Cetuximab/RT (CET/RT) is an alternative treatment option to CCRT. The efficacy of induction chemotherapy (IC) followed by chemoradiation compared to chemoradiation alone has not been demonstrated in randomized clinical trials. The goals of this phase II-III trial were to assess: (i) the overall survival (OS) of IC versus no-induction (no-IC) and (ii) the Grade 3-4 in-field mucosal toxicity of CCRT versus CET/RT. The present paper focuses on the analysis of efficacy. Materials and methods: Patients with LAHNSCC were randomized to receive concomitant treatment alone [CCRT (Arm A1) or CET/RT (Arm A2)], or three cycles of induction docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT (Arm B1) or followed by CET/RT (Arm B2). The superiority hypothesis of OS comparison of IC versus no-IC (Arms B1+B2 versus A1+A2) required 204 deaths to detect an absolute 3-year OS difference of 12% (HR 0.675, with 80% power at two-sided 5% significance level). Results: 414 out of 421 patients were finally analyzed: 206 in the IC and 208 in the no-IC arm. Six patients were excluded because of major violation and one because of metastatic disease at diagnosis. With a median follow-up of 44.8 months, OS was significantly higher in the IC arm (HR 0.74; 95% CI 0.56-0.97; P=0.031). Complete Responses (P=0.0028), Progression Free Survival (P=0.013) and the Loco-regional Control (P=0.036) were also significantly higher in the IC arm. Compliance to concomitant treatments was not affected by induction TPF. Conclusions: IC followed by concomitant treatment improved the outcome of patients with LAHNSCC without compromising compliance to the concomitant treatments. The degree of the benefit of IC could be different according to the type of the subsequent concomitant strategy.

Published
2017

37. Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study

Author

Baldari, S., primary, Annibale, V., additional, Lastoria, S., additional, Tucci, M., additional, Borsatti, E., additional, Monari, F., additional, Paganelli, G., additional, Verri, E., additional, Muto, P., additional, Panareo, S., additional, Mosca, A., additional, Storto, G., additional, Bagnato, A., additional, Farsad, M., additional, Bilancia, D., additional, Marchetti, P., additional, Sternberg, C., additional, Procopio, G., additional, Seregni, E., additional, and Valdagni, R., additional

Published
2017
Full Text
View/download PDF

38. Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and Vomiting

Author

Bossi, P, Cortinovis, D, Cossu Rocca, M, Roila, F, Seminara, P, Fabi, A, Canova, S, Verri, E, Fatigoni, S, Iannace, A, Macchi, F, Ripamonti, C, Bossi, P, Cortinovis, D, Cossu Rocca, M, Roila, F, Seminara, P, Fabi, A, Canova, S, Verri, E, Fatigoni, S, Iannace, A, Macchi, F, and Ripamonti, C

Abstract

Patients with cancer frequently use dietary supplementation and herbal therapies to control symptoms of disease and adverse effects of cancer therapy. Despite the widespread use of dietary supplementation and herbal therapies in oncology, robust scientific evidence in this area is lacking. Not only do these products need to be tested in large and well-designed observational or randomized studies, but their manufacturing process must be improved to achieve higher levels of standardization in product quality. Ginger is frequently used to counteract chemotherapy-induced nausea and vomiting (CINV), and some suggestions that it might be effective against CINV come from randomized and/or crossover clinical trials. However, several limitations in the methods of these studies limit their power and generalizability. The authors are conducting a randomized, double-blind study with a large sample size and homogeneous inclusion criteria in order to evaluate the efficacy of a well-standardized ginger extract in reducing nausea in patients with cancer. The widespread use of standardized herbal therapies and natural components among patients requires that scientific and rigorous research strategies are applied in this field to guide the physicians and the patients in safer use.

Published
2016

39. 854P - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

Author

Caffo, O., Palesandro, E., Nole, F., Gasparro, D., Mucciarini, C., Aieta, M., Zagonel, V., Iacovelli, R., De Giorgi, U.F.F., Rossetti, S., Fratino, L., Ermacora, P., Nicodemo, M., Giordano, M., Sartori, D., Scapoli, D., Verri, E., Maines, F., Pappagallo, G., and Aglietta, M.

Published
2019
Full Text
View/download PDF

41. First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study

Author

Bersanelli, M., primary, Maines, F., additional, Facchini, G., additional, Gelsomino, F., additional, Zustovich, F., additional, Santoni, M., additional, Verri, E., additional, De Giorgi, U., additional, Masini, C., additional, Morelli, F., additional, Vitale, M.G., additional, Sava, T., additional, Prati, G., additional, Librici, C., additional, Fraccon, A.P., additional, Fornarini, G., additional, Maruzzo, M., additional, Leonardi, F., additional, Caffo, O., additional, and Buti, S., additional

Published
2016
Full Text
View/download PDF

43. Clinical outcome of circulating tumor cells in metastatic castration-resistant prostate cancer patients treated with docetaxel: long-term prospective single-centre study

Author

Verri, E., primary, Aurilio, G., additional, Cossu Rocca, M., additional, Sandri, M.T., additional, Pruneri, G., additional, Botteri, E., additional, Zorzino, L., additional, Cassatella, C., additional, Adamoli, L., additional, Cullurà, D., additional, De Cobelli, O., additional, Musi, G., additional, Jereczek, B., additional, Iacovelli, R., additional, and Nolè, F., additional

Published
2015
Full Text
View/download PDF

48. 2830 A combined modality treatment with primary chemotherapy followed by Transoral Laser Microsurgery in intermediate stage laryngeal squamous cell carcinoma: A phase II study

Author

Cossu Rocca, M., primary, Chiocca, S., additional, Maffini, F., additional, Santoro, L., additional, Cattaneo, A., additional, Alterio, D., additional, Verri, E., additional, DeBenedetto, L., additional, Massaro, M., additional, Iacovelli, R., additional, Preda, L., additional, Cullurá, D., additional, Tagliabue, M., additional, Aurilio, G., additional, Lepanto, D., additional, Nolé, F., additional, and Ansarin, M., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results